| Bid | 23.8 |
| Market Cap | 2.64B |
| Revenue (ttm) | - |
| Net Income (ttm) | - |
| EPS (ttm) | -2.8 |
| PE Ratio (ttm) | -8.67 |
| Forward PE | n/a |
| Analyst | Buy |
| Ask | 25.6 |
| Volume | 353,874 |
| Avg. Volume (20D) | 943,622 |
| Open | 25.21 |
| Previous Close | 25.21 |
| Day's Range | 24.26 - 25.64 |
| 52-Week Range | 13.48 - 36.60 |
| Beta | undefined |
About ZLAB
Zai Lab Limited develops and commercializes therapies to treat oncology, autoimmune disorders, infectious diseases, and neuroscience primarily in Mainland China and Hong Kong. The company's commercial products include Zejula, a once-daily small-molecule poly polymerase 1/2 inhibitor; Optune, a device that delivers tumor treating fields; NUZYRA for acute bacterial skin and skin structure infections, and community acquired bacterial pneumonia; and ...
Analyst Forecast
According to 3 analyst ratings, the average rating for ZLAB stock is "Buy." The 12-month stock price forecast is $55, which is an increase of 126.52% from the latest price.
Next Earnings Release
Analysts project revenue of $110.52M, reflecting a 67.89% YoY growth and earnings per share of -0.78, making a -20.41% decrease YoY.
1 month ago · businesswire.com
Zai Lab Announces Participation in Investor Conference in January 2025SHANGHAI & CAMBRIDGE, Mass.--(BUSINESS WIRE)--Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9688) today announced that members of the Company's senior management team will participate in the following investor...
2 months ago · businesswire.com
Zai Lab Announces Pricing of Public Offering of American Depositary SharesSHANGHAI & CAMBRIDGE, Mass.--(BUSINESS WIRE)--Zai Lab Limited (“Zai Lab” or the “Company”) (NASDAQ: ZLAB; HKEX: 9688), an innovative, commercial-stage biopharmaceutical company, today announced the pr...
2 months ago · businesswire.com
Zai Lab Announces Proposed Public Offering of American Depositary SharesSHANGHAI & CAMBRIDGE, Mass.--(BUSINESS WIRE)--Zai Lab Limited (“Zai Lab” or the “Company”) (NASDAQ: ZLAB; HKEX: 9688), an innovative, commercial-stage biopharmaceutical company, today announced that i...
2 months ago · businesswire.com
Zai Lab Announces Third Quarter 2024 Financial Results and Recent Corporate UpdatesSHANGHAI & CAMBRIDGE, Mass.--(BUSINESS WIRE)--Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9688) today announced financial results for the third quarter of 2024, along with recent product highlights and corpo...
2 months ago · businesswire.com
Zai Lab Announces Participation in November and December Investor ConferencesSHANGHAI & CAMBRIDGE, Mass.--(BUSINESS WIRE)--Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9688) today announced that members of the Company's senior management team will participate in the following investor...